Viatris Agrees to Sell Its Biocon Biologics Holding for $815M

In a significant move reshaping its business strategy, Viatris (Nasdaq: VTRS) has agreed to sell its equity stake in Biocon Biologics Limited for a total of US $815 million, receiving $400 million in cash and $415 million in newly issued shares of Biocon Limited.This landmark deal not only unlocks value for Viatris’s shareholders but also accelerates its re-entry into the global biosimilars market without the prior constraints tied to the Biocon Biologics partnership.